![]() ![]() At year 5, participants were recalled for examination. At year 2, participants were released from the protocol to treatment at the discretion of their ophthalmologist. After initial randomization to 1 of 4 treatment groups (ranibizumab monthly, bevacizumab monthly, ranibizumab as needed, or bevacizumab as needed), at year 1, participants in the monthly groups were rerandomized to continue monthly treatment or to switch to as-needed treatment using the same drug as originally assigned. Objectives To ascertain the characteristics of eyes in the CATT that retained good vision despite receiving no therapy for 3 years after release from the 2-year CATT treatment protocol.ĭesign, Setting and Participants This case-control study analyzed the baseline and follow-up characteristics of eyes with nAMD that were enrolled in the CATT from 43 US clinical centers between February 20, 2008, and December 9, 2009. Importance Identifying the characteristics of eyes with neovascular age-related macular degeneration (nAMD) that maintain good vision without anti–vascular endothelial growth factor treatment for at least 3 years after management, as occurred in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), may have prognostic importance and help in understanding the disease and its treatment. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine. ![]() Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography. ![]()
0 Comments
Leave a Reply. |